CGEN cgen.com: Enterprise Value to EBITDA Ratio

Graphic logo of Compugen (CGEN)

Compugen Ltd. (CGEN) enjoys global recognition as an innovator in AI-driven target discovery for tumor therapies, while its digital research format minimizes environmental impact and reduces waste. This price chart illustrates the EV/EBITDA multiple, which currently stands at 0.00. However, financial stability relies on licensee payments, and R&D expenditures create a risk of losses should clinical trials fail.

Compugen Ltd - CGEN Total Company Value to Operating Income Before Depreciation Ratio (period 11/23/2025 - 11/10/2026)

Summary analytical data breakdowns for cgen.com (CGEN)

- stock price and consensus target price:
Stock Quotes Compugen|CGEN - Average Forecast Price
- company stock capitalization data:
Market Valuation Compugen Ltd.|CGEN - Value Adjusted for Debt and Cash
- business book valuation details:
Book Value per Share Compugen|CGEN - Book Valuation of Business|Market Value to Book Value Ratio cgen.com|CGEN - Cumulative Company Assets
- debt and solvency information:
Debt to Equity Compugen Ltd.|CGEN - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio Compugen|CGEN - Company Aggregate Debts|Debt to Book Capitalization Ratio Compugen Ltd.|CGEN - Company Long-Term Indebtedness|Company Short-Term Debt Compugen|Quick Liquidity Indicator cgen.com
- financial results and valuation multiples details:
CGEN - Annual Net Income|Future Profit Compugen Ltd.|CGEN - Market Price to Net Income Ratio|Forward P/E Multiple Compugen|CGEN - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Compugen Ltd.|CGEN - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Compugen|CGEN - Earnings per share for the trailing year|Quarterly EPS earnings growth cgen.com|CGEN - Earnings growth in current year|Net earnings per share growth forecast for next year Compugen Ltd.
Fundamental company analysis:CGEN (Compugen Limited)
Original product of Compugen Ltd

This indicator correlates the total business value, including net debt, with its operating profit before taxes, depreciation, and amortization. The metric determines the asset's real price by neutralizing the impact of debt load and tax regimes. An analysis of the Enterprise Value to EBITDA ratio reveals the issuer's overvaluation during periods of low liquidity. For Compugen Ltd. (CGEN), this is critical, as dependence on a single IT platform and binary development risks necessitate strict control over fundamental value.

Competitor analysis for Compugen Ltd.

ImmunityBio Corp - Enterprise Value to EBITDA Ratio|Immunocore Corp (IMCR) - Company Value to EBITDA|JANX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RCUS (arcusbio.com)|ZYME: EV/EBITDA Multiple|TNGX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Iovance|Enterprise Value to EBITDA Ratio Immatics Biotechnologies (IMTX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Xencor, Inc. (XNCR)|Enterprise Value to EBITDA Ratio compasstherapeutics.com CMPX|Replimune - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Lyell LYEL|IPHA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PYXS (Pyxis Oncology, Inc.) - Enterprise Value to Operating Income Before Depreciation|IO Biotech, Inc. (IOBT) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA sutrobio.com (STRO)|Enterprise Value to EBITDA Ratio INKT|HOWL - Enterprise Value to EBITDA Multiple|Enterprise Value to EBITDA Ratio IMMX (Immix Biopharma, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio ALXO|EV/EBITDA Multiple CUE (Cue Biopharma)|Business Value to Operating Income Before Depreciation PDSB|Sonnet BioTherapeutics Holdings Inc. - EV/EBITDA Multiple|Company Value to EBITDA MAIA Biotech|Liminatus Pharma Corp (LIMN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|LAVA Therapeutics - Business Value to Operating Income Before Depreciation|NXTC (NextCure, Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple Leap Tx|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Intensity Therapeutics (INTS)|SNSE: Company Value to Operating Income Before Depreciation Ratio|Synthetic Biologics - Enterprise Value to EBITDA Ratio|Gritstone bio Inc. (GRTS) - Company Value to EBITDA|Kineta, Inc. - EV/EBITDA Multiple|neximmune.com (NEXI) - Enterprise Value to EBITDA Ratio|turnstonebio.com (TSBX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Vaccinex Inc. (VCNX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harpoon Tx